Medical Retina

6962 Lugano-Viganello, Schweiz
Lehrkurs

Medical Retina

5th ESASO Module 2019

Datum:
08.04.2019, 08:30 - 12.04.2019, 12:45
Veranstalter:
European School for Advanced Studies in Ophthalmology ESASO
Kurzbeschreibung:
This 5th module of the ESASO training courses in 2019 will focus on medical retina. International speakers will share their knowledge. The training course will take place in Rome, Italy.
Fortbildungspunkte: beantragt

Fachärzte

Max. Teilnehmer: unbegrenzt
Gebühren ab: 2.300,00 EUR

Hinweis:
Accomodation included

Ärzte/-innen in Weiterbildung

Max. Teilnehmer: unbegrenzt
Gebühren ab: 2.300,00 EUR

Hinweis:
Accomodation included.
Bemerkungen:
Diese Veranstaltung findet jährlich statt und bietet Fortbildungsmöglichkeiten für Fachärzte und Ärzte/-innen in Weiterbildung.
Die Zertifizierung wurde bei der European Accreditation Council for Continuing Medical Education (EACCME) beantragt.
Veranstaltungsnummer: 25972
Zertifizierung: beantragt
Gebühren ab:
ab 2.300,00
verfügbare Plätze: unbegrenzt
Sprache: Englisch
 
Vom Veranstalter gemeldetes Programm:

 

   
MONDAY, 08 APRIL 2019  
   
08:30 - 09:00 Registration and welcoming
   
  OCT EXAMINATION OF THE ALTERATIONS OF THE FUNDUS OCULI IN GLAUCOMA
   
09:00 OCT Anatomy and Pathological Modifications of ONH, RNFL and GCL in Glaucoma
09:45 Confounding factors at OCT analysis for Glaucoma: Myopia, epiretinal membrane and other 
10:15 How to Combine Visual Field and OCT information 
11:00 Cases Study: OCT Glaucoma Progression Analysis
11:30 Controversial Point: SD-OCT signs for Early Diagnosis of Glaucoma are enough to start the Treatment
12:00 Controversial Point: SD-OCT signs for Early Diagnosis of Glaucoma alone not justify the start of the Treatment 
12:30 Where are we with the neuroprotection 
12:45  LUNCH
   
  NEUROPHTHALMOLOGY COURSE
   
13:30 Hemicrania with visual aura: physiopathology and complications; and difference with unilateral transient visual defect 
14:00 OCT-A signs and stadiation of Anterior Ischemic Optic Neuropathies and their correlation with FA and Visual Field findings
14:45 OCT-A differential signs from Anterior Ischemic Optic Neuropathies and Papilloedema, Glaucoma and other neuropathies 
16:00 Cases Study of Arteritis and Non-Arteritis Anterior Ischemic Optic Neuropathies 
16:45 - 17:15 Inherited optic neuropathies
   
   
   
   
TUESDAY, 09 APRIL 2019   
   
  MULTIFACETED CSC 
   
08:30 Staging of Pachychoroid spectrum 
09:00 Differential diagnosis
09:45 From acute to chronic and complicated
11:00  Mechanisms of action, indications and efficacy of treatment options 
11:45 Cases-study of CSC Management 
12:30 Lunch
   
  ATLAS OF RETINAL DYSTROPHIES
   
13:30 Genetic inheritance and mutations
14:00

Understanding the basics of visual electrophysiology and its application in inherited retinal diseases

14:30

Pathognomonic OCTA abnormalities

15:00 Cases-study of Retinitis pigmentosa
16:00 Cases-study of best disease and adult onset foveomacular vitelliform dystrophy
16:30 - 17:15 Cases-study of Stargardt diseases and other retinal dystrophies
   
   
   
   
WEDNESDAY, 10 April 2019  
   
  UVEITIS ESSENTIAL
   
08:30 Cases-study of infectious uveitis
09:30 Cases-study of non-infectious uveitis
11:00 Deliver of corticosteroids in uveitis
11:45 Modulating Immunosuppression and biologic therapy in uveitis
12:30 Lunch
13:30 - 16:30 Industry Satellite Symposia: fighting the blindness
   
   
   
   
THURSDAY, 11 April 2019  
   
  AMD REVOLUTION
   
08:30 Distinguish the CNV by position, stade of maturity, grade of activity
09:30 Predictive factors before and after the loading phase
11:00 Controversial point: PRN is better than T/E for neovascular AMD management
11:30 Controversial point: T/E is better than PRN for neovascular AMD
12:00 Cases Study of AMD with bullous PED Management and of PCV management
12:30 Lunch
13:30 OCT and OCT-A Signs of subclinical neovascularization
14:30 Controversial Point: Never Treat a Subclinical CNV
15:00 Controversial point: the threshold beyond which you must treat a subclinical CNV
16:00 Ranibizumab and aflibercept in the treatment of Myopic CNV
16:30 - 17:15 Cases Study of Myopic CNV management
   
   
   
   
FRIDAY, 12 April 2019  
   
  DR AND DME JOINED IN THE TREATMENT
   
08:30 Considering the Regression of Diabetic Retinopathy in the choice of DME treatment
09:00 How many intravitreal injections of Ranibizumab or Aflibercept for DME before consider it “non-responders”
09:45 Use of intravitreal corticosteroids as first choice, in combination with anti-VEGF, and as second choice: what the trials say
10:45 Proliferative Diabetic retinopathy, how the baseline characteristics affect the choice of treatment
11:15 Cases-Study: DME management
11:45 Cases-Study: PDR
12:15 - 12:45 Test, Certificates and farewell
   
Veranstaltungsort:
Ospedale Italiano di Lugano

Anschrift:
Via Pietro Capelli 1
6962 Lugano-Viganello, Schweiz
Veranstalter:
European School for Advanced Studies in Ophthalmology ESASO
Organisation:

European School for Advanced Studies in Ophthalmology ESASO
c/o Università della Svizzera italiana (USI)
Via G. Buffi 13
CH - 6904 Lugano
Tel.: +41 (0)58 666 46 29
Fax: +41 (0)58 666 46 19

 
Hinweis:

 

Registration required. Please contact the organizer for further information.